Mirum acquires Bluejay Therapeutics

Mirum agreed to acquire Bluejay Therapeutics. Reported deal value: $620M. Status: Pending. Sector: biotechnology. Target headquarters context: United States.

This page summarizes publicly available information about the transaction as of 2026-01-26. Figures and status may change as filings and press coverage update.

Mirum Pharmaceuticals announced the completion of its acquisition of Bluejay Therapeutics , adding a late-stage liver disease program to its pipeline and positioning the company for potential entry into the treatment of chronic hepatitis delta virus , a rare and severe condition with no approved therapies in the United States.1 HDV is a coinfection occurring in select people infected with the hepatitis B virus and is the most severe form of viral hepatitis due to its potential for rapid progression to liver cirrhosis, liver cancer, and liver-related death.1 The disease affects an estimated ...